Organic Active Ingredients TRIZ Cases

RCM-1 targets undruggable FOXM1 via ubiquitination to resolve airway inflammation and mucus hyperplasia.

3-Aminooxime derivatives of substituted androstanes address arrhythmogenic side effects by isolating pure isomers to enhance myocardial performance.

Defined crystal structures enhance FLT3 inhibitor bioavailability while reducing side effects.

A synergistic pharmaceutical composition combines L-alanyl-L-glutamine, hyaluronic acid, and oat extract to accelerate skin repair.

Hydrophilic group modification of the andrographolide core improves water solubility, enabling parenteral administration while reducing adverse reactions.

Isoindolone derivatives inhibit MEK kinase activity to treat hyperproliferative disorders and inflammatory diseases.

Indole compounds down-regulate estrogen receptors to overcome resistance in ER-positive breast cancer therapy.

Nanodroplet compositions stabilize hydrophobic drugs to prevent premature release and reduce systemic toxicity.

Pharmaceutical compositions use segmented layers to deliver CNS stimulants via controlled release mechanisms.

Antisense oligonucleotides modulate microRNA activity to detect neuroinflammation before clinical symptoms appear in neurodegenerative diseases.

Segmented biodegradable PLGA microspheres modulate diffusion to stabilize plasma concentrations, preventing withdrawal symptoms from fluctuating levels.

Detecting FGFR2 activation mutations classifies endometrial cancer subtypes, resolving the trade-off between diagnostic precision and method complexity.

A PWAR5 expression vector sustains intracellular levels to inhibit hepatitis C virus proliferation.

A flavonoid composition inhibits furin and ACE2 to block SARS-CoV-2 entry into host cells.

Subcritical liquid extraction paired with organic solvent processing yields oleandrin-containing extracts.

Enzymatic cleavage and chromatography quantify pyro-Glutamic Acid to resolve inconsistent quality assessment of glatiramer acetate manufacturing.

Selective isomer separation of rumenic acid-rich CLA resolves manufacturing complexity while delivering superior anti-inflammatory efficacy for joint health.

Polymeric nanoparticles bind endotoxins via adsorption, resolving low capacity and selectivity issues in fluid purification.

Dry-powder blending of Lenalidomide base, salts, or cocrystals ensures predictable dissolution and bioequivalence despite formulation flexibility challenges.

Cyclodextrin forms inclusion complexes with Agrimonia eupatoria extract, increasing recovery rate and bioavailability while reducing liver cell injury markers.

Formula I compounds modulate FXR activity to treat metabolic disorders while minimizing toxicities.

siRNA-mediated Smurf2 inhibition reduces lipofuscin accumulation and reactive oxygen species, addressing age-related disease mechanisms.

Novel phosphorus derivatives of nicotinamide riboside effectively boost intracellular NAD+ levels, addressing inadequate pharmacologic intervention methods.

Cell-penetrating dominant-negative ATF5 peptide inhibits transcription factor activity to promote apoptosis in neoplastic cells.

Aqueous propylene glycol vehicle with macrogol-glycerol hydroxystearate emulsifier holds low-dose clobetasol propionate for stable topical delivery.

A miRNA expression cassette directs cleavage of target mRNA sequences to inhibit viral replication.

Anionic polymerization controls polydispersity to resolve manufacturing complexity while reducing wound dehiscence in dental implant surgery.

Dual-target KSR inhibitors block kinase pathways to widen the therapeutic window for Ras-mutant cancers.

Etifoxine benzoxazine derivatives treat alcohol withdrawal syndrome with reduced adverse effects and lower dependence risk compared to benzodiazepines.

Compacted biodegradable rods eliminate interconnected open channels in PLGA matrices, controlling hydrolysis rates to extend drug release beyond three months.

Isolation layer between core and coating reduces lag time for colon targeting drug delivery.

A stable crystalline acid salt of a tricyclic derivative resists humidity absorption during pharmaceutical manufacturing.

Local quality and dynamics principles enable selective GR binding, reducing side effects from unselective interactions.

Formula G compounds inhibit Janus kinase activity, mitigating cytokine storms and acute lung injury in severe pneumonia.

A hyzetimibe tablet uses a povidone solid dispersion to maintain an amorphous drug form.

Sustained-release escitalopram gentisate injectable dosage form delivers gradual active ingredient release into the bloodstream.

Small molecule benzimidazoyl compounds replace peptide drugs to improve stability and oral bioavailability for type 2 diabetes treatment.

A pH-sensitive copolymeric sequestrant targets the distal small intestine to bind and remove pathogen-associated molecular patterns.

Tricyclic triazolo compounds inhibit diacylglycerol kinase to restore T cell antitumor immunity against resistant cancer.

Modular synthesis of deuterated amino-pyrazolopyrimidines enables scalable production of selective ATR kinase inhibitors for cancer treatment.

Galactose-derived C-glycoside compounds rectify Th-1 and Th-2 lymphocyte imbalances to prevent chronic inflammation from environmental stress.

A drug delivery coating uses a cationic agent to enhance therapeutic uptake.

A pharmaceutical agent combining citrulline and glutathione to enhance nitric oxide production in vascular endothelial cells.

Polymethine dyes target tissue-specific transporters on nanostructured carriers, resolving the contradiction between passive delivery and systemic side effects.

Alpha lipoic acid paired with proton pump inhibitors delivers rapid symptom relief, overcoming the slow onset of traditional single-agent therapies.

Fluorine-substituted triazolopyridines resolve receptor desensitization and improve selectivity for treating central nervous system disorders.

Optimized Mcl-1 inhibitor formulations resolve clinical readiness gaps by ensuring therapeutic efficacy against resistant malignancies.

Homoisoflavonoids and flavonoid monoglucosides synergistically inhibit intestinal glucose transporters to reduce post-prandial blood sugar levels.